Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference summary

Strategic transformation and leadership

• Leadership overhaul and strategic pivot led to accelerated clinical programs and extended financial runway, now reaching Q2 2028, excluding partner milestones.

• New management emphasizes disciplined execution, platform differentiation, and a coherent organization linking discovery, process, and clinical development.

Technology and pipeline advancements

• Proprietary ADC platform enables optimization of all ADC components, including antibody, linker, and payload, with cell-free synthesis and click chemistry.

• Pipeline includes single and dual payload ADCs, with three INDs targeted over the next two years.

• Dual payload technology allows precise control of payload ratios, aiming to overcome resistance and improve safety and efficacy.

Clinical progress and data outlook

• STRO-004, a tissue factor ADC, is in clinical trials with a high safety window (HNSTD 50 mg/kg) and broad tumor applicability beyond cervical cancer.

• Top-line phase I data for STRO-004 expected mid-year, focusing on tolerability, PK, and early efficacy signals across multiple tumor types.

• Integrin beta-6 (STRO-006) and PTK7 dual payload programs are advancing, with the latter's timeline accelerated to late 2024.